Day 1
Sunday
Feb. 8, 2004

9 am-12 noon

Hands-On Computer Workshop
1. HIV Sequence, Immunology and Vaccine Databases
 

9 am-3 pm

2. Program
Committee
Workshop
for New
Investigators
and Trainers
(domestic & international)
 

3-5 pm

Symposium
3. Developments
in
the Global Response to AIDS

5. Molecular Virology and Pathogenesis of Hepatitis C
 

14. HLA Imprinting: Implications for Selection of Vaccine Immunogens
 

24. HIV Vaccine Efficacy Trials: Lessons Learned and Future Directions
 

Post-Conference  Workshop

Pharmacological Monitoring of Complex Patient Treatment Scenarios
 

6. How Close Are We to an Effective Microbicide?
 

15. DNA Editing and Host Resistance Factors
 

25. TB/HIV: Is there a Scientific Basis for Hope?
 

Break

7. Immune Responses to HIV

8. Acute/Recent Infection

9. Neuropathogenic Manifestations of HIV Infection
(includes 1 Minilecture:  Peripheral Neuropathy Associated with HIV and ARV: Update on Diagnosis and Management)

10. Transmission, Selection, and Persistence of Drug Resistant Virus
(includes 1 Minilecture: Maternal and Infant Treatment Strategies for Preventing MTCT)

16. Viral Genes and Cellular Co-Factors

17. Complications of HIV Infection and Antiretroviral Therapy

26. Retroviral Pathogenesis

27. Pharmacology and New Antiretroviral Agents

    Lunch

     Poster Sessions
 see poster sessions grid below for session titles

Poster Sessions
 see poster sessions grid below for session titles

Poster Discussion Group

Trans-
mission of Drug Resistance HIV: Conflicting Trends and Clinical Significance

1-4 pm

20. Hands-On Computer Workshop

HIV Sequence, Immunology and Vaccine Databases

Poster Discussion Group

New Insights into Intracellular and Plasma Pharma-cokinetics of Antiretro-virals

Poster Discussion Group

HPV Infection and Anal Cancer

Break

5:30-7 pm
4. Opening Session

Ninth Annual Bernard Fields Memorial Lecture
Wesley Sundquist
 

Keynote Lecture Ambassador Stephen H Lewis
 

Symposium
11. Virus-Host Cell Synapses

Symposium
12. Emerging Long Term Complications of HIV and its Therapies in Children, Adolescents and Women

Oral Abstract Session
13. Antiretroviral Therapy: Emergence, Mechanisms, and Persistence of Resistance

Symposium
21. Host Restriction Factors

Symposium
22. HIV Vaccines:
Clinical Trial Results
Call for More Basic Science

Oral Abstract Session
23. HIV/HCV Co-Infection

Symposium
31. Advances in the Science of Antiretroviral Therapy: Drug Discovery to Global Strategy

Oral Abstract Session
32. Clinical and Preclinical Vaccine Studies

Monday, Feb. 9, 2004

Tuesday, Feb. 10, 2004

Wednesday, Feb. 11, 2004

Poster Hall Open
All posters will be available for viewing for the duration of the conference.

Poster Sessions

40. T-Cell Responses in Adults

41. T-Cell Responses in Children

42. HLA and Immunity

43. Cellular Responses under HAART

53. Viral Envelopes: Structure-Function Studies

54. Virus Entry, Receptors, and Co-Receptors

55. Viral Replication: Uncoating, RT, and Integration

56. Viral Replication: Post-Integration Events

80. Antiretroviral Therapy: Predictors of Response and Virologic Failure

81. Antiretroviral Treatment Strategies

95. Transmission of Drug Resistant HIV-1: Conflicting Trends and Clinical Significance

96. Prevalence of Drug Resistance: Cohort Studies

97. Impact of Virus Type/Subtype on Resistance Development

98. Drug Resistance Testing: New Methods, Interpretations, and Reproducibility

99. Pathogenetic Mechanisms of Abnormalities of Glucose, Insulin, Lipid, and Mitochondrial Metabolism

100. Dyslipidemias and Body Fat Abnormalities:  Incidence, Risk Factors, Response to Therapy

103. Bone Metabolism Abnormalities

104. Systemic and Organ Complications of HIV-1 and Antiretroviral Therapies

117. Incidence of HIV-1 Infection

118. Access to Care and Antiretroviral Therapy

119. Descriptive Epidemiology and Testing

120. Morbidity and Mortality of HIV-1 Infection

121. In Vitro Microbicide Testing

122. Clinical Interventions

126. Antiretroviral Therapy in Pregnant Women

127. Antiretroviral Therapy in Children

131. Natural History of HIV-1 and Antiretroviral Treatment Response in Women

132. HIV Expression in the Female Genital Tract

Poster Sessions

44. Lymphocyte Immunophenotyping in SIV Infection

45. Natural Killer Cell Subsets

46. Cytokine Studies

47. Dendritic Cells

48. Correlates of Resistance to Infection

60. Primary Infection: Viral Pathogenesis

61. Primary Infection: Cellular Immunity

62. Primary Infection: Treatment Trials and STIs

63. Host Genetic Factors

64. Viral Tropism and Coreceptor Use

65. Viral Targets and Reservoirs

66. Virus Neutralization

67. Viral Replication: Cytokine Effects

73. Neuropathogenesis: Animal Models and Mechanisms of Neuro Invasion

74. Neuropathogenesis: Therapy and Clinical/Pre-Clinical Studies

75. Neuropathogenesis: Clinical Correlates and Observational Studies

76. General and Virus-Specific Immune Augmentation Strategies

84. New Insights into Intracellular and Plasma Pharmacokinetics of Antiretrovirals

85. Pharmacology of Reverse Transcriptase Inhibitors

86. Pharmacology of Protease Inhibitors

87. Activity of Drugs against Resistant Viruses

88. Mechanisms of Drug Resistance and Increased Susceptibility

93. Interplay between STI's and Drug Resistance

94. Resistance Predictors of Virologic Response and Clinical Outcome

101. Cardiovascular Complications: Pathogenesis

102. Cardiovascular Complications: Risk Factors, Incidence, Prevalence, and Outcomes

105. Atypical Mycobacterial and Tuberculous Opportunistic Infections

106. Non-Mycobacterial Opportunistic Infections

110. Epidemiology and Natural History of HIV-HCV Co-Infection

115. Risk Behavior

116. Parenteral Transmission of HIV-1 Infection

123. Mother-to-Child Transmission

124. Viral Pathogenesis in Mothers and Children

133. Viral Load Monitoring

134. Simplified CD4 Monitoring

135. Antibody Detection

Poster Sessions

49. Designing Vaccine Immunogens

50. Vaccine Immunogenicity

51. Immune Responses in SIV/SHIV Infections

52. Vaccine Clinical Trials

57. Viral Replication: Positive and Negative Host Co-Factors

58. Viral Replication: Virus-Cell Interactions

59. Viral Lineages and Evolution

68. Mechanisms of Lymphocyte Dysfunction

69. Viral Recombination and Superinfection

70. Plasma Viremia

71. Neuropathogenesis: Viral Co-Factors

72. Neuropathogenesis: Host Co-Factors

77. New Antiretroviral Agents: RTI's and PI's

78. New Antiretroviral Agents: Entry Inhibitors

79. New Antiretroviral Agents: Novel Approaches

82. HIV in Resource Limited Settings: Clinical Manifestations and Testing Strategies

83. Antiretroviral Agents in Resource Limited Settings

89. Impact of Drug Resistance on Viral Fitness

90. Evolution of Drug Resistance

91. Pathogenesis and Persistence of Drug Resistance

92. Emergence of Resistance to Specific Drugs and Drug Combinations

107. HPV Infection and Anal Cancer

108. Opportunistic Malignancies: Kaposi's Sarcoma and Lymphomas

109. HCV Pathogenesis

111. Therapy of HCV in HIV Co-Infected Individuals

112. HIV-HCV Co-Infection: Organ Transplantation and Malignancy

113. HAV and HBV: Prevention and Treatment Issues in HIV Infected Persons

114. Molecular Epidemiology of HIV-1 Infection

125. Pregnant Women and Children: Immunology

128. Treatment in Pregnant Women and Children: Pharmacokinetics

129. Treatment in Pregnant Women and Children: Toxicity

130. Treatment in Pregnant Women and Children: Treatment Interruptions

Poster Discussion Group 

95. Transmission of Drug Resistant HIV-1:
Conflicting Trends and Clinical Significance

Poster Discussion Group 

84. New Insights into Intracellular and Plasma Pharmacokinetics of Antiretrovirals

Poster Discussion Group 

107. HPV Infection and Anal Cancer